INTERACT Meeting Timing Remains Point Of Confusion

US FDA review divisions will determine whether the meeting is appropriate because there are no one-size-fits-all requirements.

ambiguity
The development timing for an INTERACT meeting remains a regulatory gray area. • Source: Shutterstock

More from Review Pathways

More from Conferences